US biopharmaceutical firm Adolor Corp says that it has priced a public offering of five million shares of its common stock at $25.00 per share. The net proceeds are expected to be around $117.0 million. The closing of the offering is expected to occur on February 22, subject to the satisfaction of customary closing conditions. Lehman Brothers is acting as the sole bookrunning manager in the offering. Pacific Growth Equities, Banc of America Securities and JP Morgan Securities are co-managers. Adolor has granted the underwriters an option to purchase up to an additional 750,000 shares within 30 days after the offering.
The company plans on using the net proceeds for general corporate purposes, which may include increasing its working capital, acquisitions, in-licensing of products or technologies and capital expenditures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze